TBTC launches CRUSH-TB trial
CDC’s Tuberculosis Trials Consortium (TBTC) has recently launched the CRUSH-TB trial, which aims to identify new combinations of drugs to shorten treatment of active TB disease. Kelly Dooley, MD, PhD, MPH, Director, Division of Infectious Diseases, is a Protocol Chair for this new study.
“CDC’s TBTC launched an international clinical trial, Combination Regimens for Shortening Tuberculosis Treatment, or CRUSH-TB, to identify new combinations of drugs to shorten treatment of TB disease. These new regimens may improve drug tolerability and minimize drug interactions, giving healthcare providers more options to treat TB disease and completion of treatment."
